Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $65.71M
• Dividend Yield: N/A
• Average Volume (3M): 883.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -43.88%
• EPS Growth: 4.73%
• Country: US
• Employees: 202
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 37,546,436
• 10 Day Avg. Volume: 1,405,864
• 30 Day Avg. Volume: 883,524
• PEG Ratio: -0.12
• Price to Book (P/B): 0.58
• Price to Sales (P/S): 2.58
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: -1.63
• Enterprise Value/Revenue: -3.46
• Enterprise Value/Gross Profit: -15.11
• Enterprise Value/Ebitda: 1.27
• 1Y Price Target: $8.67
• Price Target Upside: 395.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.50 ▼(-14.29% Downside)

Metagenomi, Inc. faces significant challenges with profitability and cash flow, reflected in a low valuation score. Technical indicators suggest bearish momentum. However, recent corporate events show strategic initiatives that could improve long-term prospects.

Positive Factors

Strategic Partnerships

The partnership with Acuitas allows Metagenomi to leverage advanced lipid nanoparticle technology, enhancing its gene-editing capabilities and expanding market reach.

Product Development

The promising preclinical results for MGX-001 highlight Metagenomi's potential to develop effective therapies, strengthening its product pipeline and market position.

Leadership Change

The appointment of a new CEO with strategic focus aims to enhance operational efficiency and drive the company towards its long-term goals.

Negative Factors

Profitability Challenges

Persistent profitability issues suggest high operational costs, which could hinder financial sustainability and require strategic cost management.

Cash Flow Concerns

Ongoing negative cash flows indicate potential liquidity challenges, necessitating careful cash management to ensure operational continuity.

Revenue Growth Volatility

Significant volatility in revenue growth may reflect market uncertainties or operational inefficiencies, impacting long-term growth prospects.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

Metagenomi, Inc. (MGX) is a biotechnology company focused on developing innovative gene editing technologies and therapeutic solutions for genetic disorders. Operating primarily in the biotechnology and life sciences sectors, Metagenomi leverages its proprietary gene-editing platform to create precise, efficient, and safe gene therapies. The company's core products include gene-editing tools that enable targeted modifications to the genome, with applications across various therapeutic areas, including rare diseases, cancer, and infectious diseases.

How the Company Makes Money

Metagenomi generates revenue through multiple streams, primarily by partnering with pharmaceutical and biotechnology companies to develop and commercialize gene therapies. The company engages in strategic collaborations, licensing agreements, and research partnerships, which provide upfront payments, milestone payments, and royalties on sales of therapeutic products developed using its technology. Additionally, Metagenomi may receive funding from government grants and private investments aimed at advancing its research and development initiatives. Significant partnerships with established firms in the biotech space enhance its revenue potential by expanding its access to markets and resources.

Metagenomi, Inc. Financial Statement Overview

Summary

Metagenomi, Inc. shows strong revenue growth but faces significant profitability and cash flow challenges. The balance sheet is improving with positive equity, but liquidity and operational efficiency need attention.

Income Statement

Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.

Balance Sheet

The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.

Cash Flow

Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.91M	52.30M	44.76M	17.20M	243.00K
Gross Profit	7.08M	52.30M	-49.65M	15.47M	-144.00K
EBITDA	-84.58M	-83.49M	-74.28M	-39.19M	-20.75M
Net Income	-88.74M	-78.06M	-68.25M	-43.59M	-21.44M
Balance Sheet
Total Assets	247.94M	324.60M	364.84M	414.49M	141.99M
Cash, Cash Equivalents and Short-Term Investments	184.11M	248.31M	271.18M	362.13M	108.15M
Total Debt	41.66M	45.78M	48.23M	18.57M	48.93M
Total Liabilities	69.49M	89.74M	149.67M	488.91M	174.54M
Stockholders Equity	178.45M	234.86M	215.17M	-74.43M	-32.54M
Cash Flow
Free Cash Flow	-92.44M	-112.19M	-101.22M	15.75M	21.35M
Operating Cash Flow	-91.62M	-109.07M	-91.41M	29.72M	24.26M
Investing Cash Flow	99.71M	-88.16M	45.73M	-122.20M	-74.32M
Financing Cash Flow	-430.00K	84.01M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Neutral. The current price of 1.75 is above the 20-day moving average (MA) of 1.71, below the 50-day MA of 2.12, and below the 200-day MA of 1.92, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.05 is Neutral, neither overbought nor oversold. The STOCH value of 45.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	55 Neutral	$128.77M	7.98	―	―	51.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORMP	47 Neutral	$117.82M	2.94	24.38%	―	―	814.20%
HOWL	45 Neutral	$32.49M	-0.39	-122.43%	―	-100.00%	-8.30%
MGX	42 Neutral	$65.71M	-0.72	-40.87%	―	-43.88%	4.73%
IMUX	37 Underperform	$72.57M	-0.66	-398.50%	―	―	30.16%
CNTX	37 Underperform	$110.26M	-3.97	-33.68%	―	―	69.30%

Metagenomi, Inc. Corporate Events

Metagenomi Announces Positive Preclinical Data for MGX-001

On November 11, 2025, Metagenomi, Inc. announced positive preclinical data from its MGX-001 hemophilia A program, demonstrating curative FVIII activity in non-human primates. The company is prioritizing its MGX-001 program and other advanced therapeutics while reducing its workforce by 25% to extend its cash runway into the fourth quarter of 2027. Jian Irish has been appointed as the new CEO, succeeding Brian Thomas, who remains on the Board. This strategic shift is expected to enhance Metagenomi’s focus on its most promising programs and maintain financial discipline.

Metagenomi Regains Control After Affini-T Agreement Termination

On September 29, 2025, Metagenomi, Inc. entered into a Non-Exclusive License Agreement with Acuitas Therapeutics, Inc. to utilize Acuitas’s lipid nanoparticle technology for developing and commercializing genome editing constructs. This agreement involves financial commitments, including maintenance fees, milestone payments, and royalties. The agreement can be terminated under specific conditions. On September 30, 2025, Metagenomi terminated its agreement with Affini-T Therapeutics, regaining full control over its intellectual property and manufacturing rights related to TCR-based therapeutic products, as Affini-T assigned its benefits to creditors. This termination allows Metagenomi to freely operate in previously restricted areas without future payments from Affini-T.